The Quantellect read.As of Nov 19, 2026, 16 active firms cover Spyre Therapeutics Inc: 15 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $80.00 to $130.00, a moderate spread. The average target of $108.40 sits 7% above the current $101.43. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 13 to 15 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.92 next quarter toward $-3.69 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 active firms
Buy
Strong Buy16%
Buy1488%
Neutral16%
Sell00%
Strong Sell00%
Based on 16 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$108.40
+6.9% upside
Average target across 15 active firms as of Nov 19, 2026 vs $101.43 current
Highest Target$130.00
Average Target$108.40
Lowest Target$80.00
Detailed analyst forecasts for SYRE
Showing 1–16 of 16 named analysts shown · 16 active firms in the rating projection
As of Nov 19, 2026, 15 of 16 active firms rate SYRE a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SYRE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.92
Range $-1.10 – $-0.67 · 4 analysts · +25% YoY
Next period, 4 analysts expect Spyre Therapeutics Inc. to earn $-0.92 a share (range $-1.10 – $-0.67), versus $-0.74 a year earlier. Full-year consensus is $-3.04, growing to $-3.69 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Spyre Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SYRE.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$123.00+21.3% to target
Overall win rate
48%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #84
Buy
$135.00+33.1% to target
Overall win rate
50%
+ Follow
#3
Julian Harrison
BTIG · Rank #183
Buy
$121.00+19.3% to target
Overall win rate
41%
+ Follow
#4
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$119.00+17.3% to target
Overall win rate
41%
+ Follow
#5
Thomas Smith
Leerink Partners · Rank #412
Buy
$128.00+26.2% to target
Overall win rate
41%
+ Follow
SYRE stock forecast FAQ
What is SYRE's average 12-month price target?+
The 15 active firms with a live target average $108.40 for Spyre Therapeutics Inc. over the next 12 months, ranging from a $130.00 high to a $80.00 low, as of Nov 19, 2026.
Is SYRE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 16 active firms as of Nov 19, 2026, 15 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SYRE?+
The Street-high target is $130.00 (Guggenheim), and the Street-low is $80.00 (Raymond James). The average of all 15 active-firm targets is $108.40.
How many active Wall Street firms cover SYRE?+
16 active firms have a recognized rating on Spyre Therapeutics Inc. as of Nov 19, 2026, and 15 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SYRE?+
Among analysts who currently cover SYRE, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $123.00 target.
What is Spyre Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.92 per share (range $-1.10 – $-0.67) across 4 analysts. Full-year EPS is projected at $-3.04, rising to $-3.69 the following year.
How much revenue is Spyre Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading SYRE lately?+
As of Nov 19, 2026, 15 of 16 active firms rate SYRE a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SYRE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.